SCHEMBL6349361

SCHEMBL6349361

CC(=O)N(CC(=O)c1ccccc1)[C@@H](C(=O)O)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
USP2 O75604 1/20 0.45
KMT2A Q03164 4/20 0.44
TSHR P16473 1/20 0.42
ADAMTS4 O75173 1/20 0.41
MAPT P10636 4/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 2/20 0.40
MEN1 O00255 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
CES1 P23141 1/20 0.40
AGTR1 P30556 1/20 0.40
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350978 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6356051 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6347733 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6354208 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6347856 0.88 ALDH1A1 (0.43) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6359362 0.88 TSHR (0.42) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6358298 0.88 TSHR (0.42) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6345066 0.87 ALDH1A1 (0.42) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6350485 0.84 KMT2A (0.44) ALDH1A1KDM4EUSP2KMT2ATSHR
SCHEMBL6352444 0.84 TSHR (0.41) ALDH1A1KDM4EUSP2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 ALDH1A1 420/4885KDM4E 2934/4885USP2 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.